Ultragenyx Pharmaceutical Inc. (RARE) — SEC Filings
Ultragenyx Pharmaceutical Inc. (RARE) — 48 SEC filings. Latest: 8-K (Apr 2, 2026). Includes 31 8-K, 6 10-Q, 6 SC 13G/A.
View Ultragenyx Pharmaceutical Inc. on SEC EDGAR
Overview
Ultragenyx Pharmaceutical Inc. (RARE) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 2, 2026: Ultragenyx Pharmaceutical Inc. filed an 8-K on April 2, 2026, reporting other events. The filing does not contain specific financial figures or new material agreements at this time.
Sentiment Summary
Across 48 filings, the sentiment breakdown is: 1 bearish, 46 neutral, 1 mixed. The dominant filing sentiment for Ultragenyx Pharmaceutical Inc. is neutral.
Filing Type Overview
Ultragenyx Pharmaceutical Inc. (RARE) has filed 31 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 6 SC 13G/A, 1 SC 13G with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (48)
Risk Profile
Risk Assessment: Of RARE's 37 recent filings, 1 were flagged as high-risk, 14 as medium-risk, and 22 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $159.9M |
| Net Income | -$180.4M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $202.5M |
| Operating Margin | N/A |
| Total Assets | $1.19B |
| Total Debt | N/A |
Key Executives
- Shehnaaz Suliman
- Matthew Fust
Industry Context
The rare disease pharmaceutical sector is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like Ultragenyx focus on niche markets with unmet medical needs, often leading to high drug prices but also requiring substantial investment in pipeline development and commercialization.
Top Tags
8-K (9) · regulatory-filing (7) · 8-k (6) · disclosure (5) · financial-reporting (5) · sec-filing (4) · 10-Q (4) · pharmaceutical (4) · financials (4) · corporate-governance (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss (Q3 2025) | $180.4M | Increased from $133.5M in Q3 2024, indicating widening losses. |
| Net Loss (YTD Sep 2025) | $446.4M | Increased from $435.8M in YTD Sep 2024, showing continued unprofitability. |
| Total Revenues (Q3 2025) | $159.9M | Increased from $139.5M in Q3 2024, driven by product sales and royalties. |
| Product Sales (Q3 2025) | $94.99M | Increased from $77.25M in Q3 2024, contributing to revenue growth. |
| Research and Development Expenses (Q3 2025) | $216.2M | Increased significantly from $170.1M in Q3 2024, driving higher operating expenses. |
| Cash and Cash Equivalents (Sep 30, 2025) | $202.5M | Decreased from $173.7M at Dec 31, 2024, reflecting cash burn. |
| Total Assets (Sep 30, 2025) | $1.19B | Decreased from $1.50B at Dec 31, 2024, indicating asset erosion. |
| Common Stock Shares Outstanding (Oct 30, 2025) | 96,477,569 | Increased from 92,484,330 at Dec 31, 2024, suggesting potential dilution. |
| SEC File Number | 001-36276 | Identifies the company's filing history with the SEC. |
| IRS Employer Identification No. | 27-2546083 | Company's tax identification number. |
| Total Revenue | $120.3M | Increased from $98.7M in Q2 2024, showing 21.9% growth. |
| Net Loss | -$105.6M | Improved from -$115.2M in Q2 2024, indicating narrowing losses. |
| Loss Per Share | -$1.25 | Improved from -$1.40 in Q2 2024. |
| R&D Expenses | $100.5M | Decreased from $110.2M in Q2 2024, reflecting cost management. |
| SG&A Expenses | $90.1M | Slightly decreased from $92.5M in Q2 2024. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Ultragenyx Pharmaceutical Inc. (RARE)?
Ultragenyx Pharmaceutical Inc. has 48 recent SEC filings from Jan 2024 to Apr 2026, including 31 8-K, 6 10-Q, 6 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of RARE filings?
Across 48 filings, the sentiment breakdown is: 1 bearish, 46 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Ultragenyx Pharmaceutical Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Ultragenyx Pharmaceutical Inc. (RARE) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Ultragenyx Pharmaceutical Inc.?
Key financial highlights from Ultragenyx Pharmaceutical Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for RARE?
The investment thesis for RARE includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Ultragenyx Pharmaceutical Inc.?
Key executives identified across Ultragenyx Pharmaceutical Inc.'s filings include Shehnaaz Suliman, Matthew Fust.
What are the main risk factors for Ultragenyx Pharmaceutical Inc. stock?
Of RARE's 37 assessed filings, 1 were flagged high-risk, 14 medium-risk, and 22 low-risk.
What are recent predictions and forward guidance from Ultragenyx Pharmaceutical Inc.?
Forward guidance and predictions for Ultragenyx Pharmaceutical Inc. are extracted from SEC filings as they are enriched.